FrancophonIA/ELRC3.0 huggingface dataset:
English: The CVMP concluded that the benefits of Zulvac 1+8 Bovis exceed the risks for prevention of viraemia caused by bluetongue virus serotypes 1 and 8 in cattle from three months of age and recommended that Zulvac 1+8 Bovis be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini Zulvac 1+8 Bovis kasulikkus vähemalt 3 kuu vanuste veiste immuniseerimisel, mille eesmärk on ennetada lammaste katarraalse palaviku viiruse serotüüpide 1 ja 8 põhjustatud vireemiat, on suurem kui sellega kaasnevad riskid, ning soovitas anda vaktsiini Zulvac 1+8 Bovis müügiloa.
English: Zulvac 1+8 Bovis was studied in calves in four main studies carried out in a laboratory.
Estonian: Vaktsiini Zulvac 1+8 Bovis uuriti vasikate neljas laboratoorses põhiuuringus.
English: A field study was also conducted investigating the safety of the vaccine in dairy cows, including pregnant and lactating cows.
Estonian: Ühes väliuuringus uuriti vaktsiini ohutust lüpsilehmadel, sh tiinetel lüpsilehmadel.
English: The field study showed that the vaccine can be used safely in pregnant and lactating cows.
Estonian: Väliuuring näitas, et vaktsiini tohib kasutada lehmadel tiinuse ja laktatsiooni ajal.
English: Zulvac 1+8 Bovis is a vaccine that contains inactivated (killed) bluetongue serotypes 1 and 8 viruses as the active substance.
Estonian: Zulvac 1+8 Bovis on vaktsiin, mis sisaldab toimeainena lammaste katarraalse palaviku inaktiveeritud (hävitatud) viiruse serotüüpe 1 ja 8.
English: Zulvac 1+8 Bovis is a vaccine.
Estonian: Zulvac 1+8 Bovis on vaktsiin.
English: The withdrawal period for Zulvac 1 + 8 Bovis for meat and milk is zero days.
Estonian: Vaktsiini Zulvac 1+8 Bovis keeluaeg liha ja piima korral on 0 päeva.
English: Zulvac 1+8 Bovis contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
Estonian: Zulvac 1+8 Bovis sisaldab lammaste katarraalse palaviku viirust, mis on inaktiveeritud (hävitatud) ega suuda seetõttu haigust tekitada.
English: immune system recognises the viruses as ‘foreign' and makes antibodies against them.
Estonian: Kui veistele manustatakse vaktsiini, peab immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: What is Zulvac 1+8 Bovis?
Estonian: Mis on Zulvac 1+8 Bovis?
English: This means that it was not possible at the time of the initial authorisation to obtain complete information about Zulvac 1+8 Bovis.
Estonian: See tähendab, et vaktsiini Zulvac 1+8 Bovis kohta ei ole olnud esmase müügiloa andmisel võimalik saada täielikku teavet.
English: How does Zulvac 1+8 Bovis work?
Estonian: Kuidas Zulvac 1+8 Bovis toimib?
English: Why has Zulvac 1+8 Bovis been approved?
Estonian: Miks vaktsiin Zulvac 1+8 Bovis heaks kiideti?
English: What is the risk associated with Zulvac 1+8 Bovis?
Estonian: Mis riskid vaktsiiniga Zulvac 1+8 Bovis kaasnevad?
English: Other information about Zulvac 1+8 Bovis:
Estonian: Muu teave vaktsiini Zulvac 1+8 Bovis kohta
English: How has Zulvac 1+8 Bovis been studied?
Estonian: Kuidas vaktsiini Zulvac 1+8 Bovis uuriti?
English: Zulvac 1+8 Bovis is used in cattle to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
Estonian: Vaktsiini Zulvac 1+8 Bovis kasutatakse veiste kaitsmiseks lammaste katarraalse palaviku eest.
English: The virus exists in several forms (serotypes) throughout the world; the types used in Zulvac 1+8 Bovis are serotypes 1 and 8.
Estonian: Vaktsiinis Zulvac 1+8 Bovis kasutatakse serotüüpe 1 ja 8.
English: What benefit has Zulvac 1+8 Bovis shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Zulvac 1+8 Bovis kasulikkus?
English: Further doses are given at the end of weeks 8 and 12.
Estonian: Lisaannused manustatakse 8. ja 12. nädala lõpus.
English: The full EPAR for Nulojix can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Nulojixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: A risk management plan has been developed to ensure that Nulojix is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Nulojixi võimalikult ohutu kasutamine.
English: Belatacept has been designed to attach to two of these molecules called CD80 and CD86.
Estonian: Belatatsept kinnitub neist molekulidest kahele - CD80-le ja CD86-le.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Nulojix on 17 June 2011.
Estonian: Euroopa Komisjon andis Nulojixi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. juunil
English: What measures are being taken to ensure the safe and effective use of Nulojix?
Estonian: Mis meetmed võetakse, et tagada Nulojixi ohutu ja efektiivne kasutamine?
English: The most common serious side effects of Nulojix seen in more than 2% of patients are: urinary tract infection (infection of the structures that carry urine), cytomegalovirus infection, pyrexia (fever), increased blood creatinine (a marker of kidney problems), pyelonephritis (kidney infection), diarrhoea, gastroenteritis (diarrhoea and vomiting), poor functioning of the transplanted kidney, leucopenia (low white blood cell counts), pneumonia (infection of the lungs), basal cell carcinoma (a cancer), anaemia (low red blood cell counts), dehydration.
Estonian: Nulojixi kõige sagedamad rasked kõrvalnähud, mis esinesid enam kui 2%-l patsientidest, olid urotraktiinfektsioon (kuseteede infektsioon), tsütomegaloviirusinfektsioon, palavik, vere kreatiniinisisalduse suurenemine (kreatiniin on neerufunktsiooni marker), neeruvaagnapõletik, kõhulahtisus, gastroenteriit (kõhulahtisus koos oksendamisega), siiratud neeru funktsioonihäire, leukopeenia (valgeliblede vähesus), kopsupõletik, basaalrakuline kartsinoom (vähk), aneemia (punaliblede arvu vähenemine), vedelikukaotus.
English: In the initial phase it is given at a dose of 10 mg per kilogram body weight on day 1 (day of transplantation or the day before) and then again on days 5, 14 and 28.
Estonian: Ravi algfaasis manustatakse ravimit 10 mg kehakaalu kg kohta 1. ravipäeval (siirdamise päeval või üks päev enne) ning seejärel uuesti 5., 14. ja 28. päeval.
English: The studies also looked at the number of organ rejections that occurred within one year of the transplant.
Estonian: Uuringutes hinnati ka äratõukereaktsioonide arvu ühe aasta jooksul pärast siirdamist.
English: Nulojix belatacept
Estonian: Nulojix belatatsept
English: Other information about Nulojix
Estonian: Muu teave Nulojixi kohta
English: T cells must be ‘activated' before they work.
Estonian: T-rakud tuleb enne toimima hakkamist aktiveerida.
English: Nulojix must not be used in patients who have not been exposed to the Epstein-Barr virus or in whom previous exposure is uncertain.
Estonian: Nulojixi ei tohi kasutada patsientidel, kellel pole olnud varasemat kokkupuudet Epstein-Barri viirusega või kelle varasem kokkupuude selle viirusega on ebaselge.
English: This is because patients treated with Nulojix who have had no previous exposure to the virus are at higher risk of getting a type of cancer known as post-transplant lymphoproliferative disorder.
Estonian: See on tingitud asjaolust, et Nulojixiga ravi saavatel patsientidel, kes pole varem selle viirusega kokku puutunud, on suurem risk haigestuda teatud vähki, mida nimetatakse siirdamisjärgseks lümfoproliferatiivseks häireks.
English: The CHMP therefore concluded that Nulojix's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu järeldas inimravimite komitee, et Nulojixi kasulikkus on suurem kui sellega seotud riskid, ja soovitas anda ravimi müügiloa.
English: Doses are calculated using the patient's weight.
Estonian: Annused arvutatakse patsiendi kehamassi järgi.
English: The main measures of effectiveness were the proportion of patients who survived with their transplanted kidneys intact and how well their kidneys functioned.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide osakaal, kes jäid elama siiratud kahjustamata neeruga, ja nende neerufunktsioon.
English: For more information about treatment with Nulojix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Nulojixiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (samuti Euroopa avaliku hindamisaruande osa) või pöörduge arsti või apteekri poole.
English: After the initial phase, which lasts three months, Nulojix is given at a maintenance dose of 5 mg/kg every four weeks starting from the end of the week 16.
Estonian: Pärast kolm kuud kestvat algfaasi manustatakse Nulojixi säilitusannus 5 mg/kg üks kord nelja nädala jooksul; ravi algab 16. nädala lõpus.
English: This happens when certain molecules attach to receptors on the surface of the T cells.
Estonian: See juhtub, kui T-rakkude pinnal olevatele retseptoritele kinnituvad teatud molekulid.
English: This is a summary of the European public assessment report (EPAR) for Nulojix.
Estonian: See on ravimi Nulojix Euroopa avaliku hindamisaruande kokkuvõte.
English: In addition, the company that makes Nulojix will include an alert card in each medicine's pack to increase awareness of the benefits and risks with Nulojix.
Estonian: Nulojixi tootev ettevõte varustab lisaks kõik ravimipakendid hoiatuskaardiga, et parandada teadlikkust Nulojixiga kaasnevatest riskidest ja kasuteguritest.
English: Nulojix is given as an infusion into a vein over 30 minutes.
Estonian: Nulojixi manustatakse tilgutiga veeni 30 minuti jooksul.
English: Nulojix was shown to improve patient and organ survival following kidney transplantation.
Estonian: Nulojix parandas patsientide ja organite elulemust pärast neerusiirdamist.
English: The CHMP noted that Nulojix does not have the toxic effects on the kidneys seen with other immunosuppressive medicines commonly used in transplantation.
Estonian: Inimravimite komitee leidis, et Nulojixil puudub neerudele toksiline toime, mida täheldatakse muudel tavaliselt siirdamise korral kasutatavatel immuunsupressiivsetel ravimitel.
English: In two main studies involving 1,209 patients who underwent a kidney transplant, Nulojix was compared with cyclosporine A (another medicine used to prevent organ rejection).
Estonian: Kahes põhiuuringus, milles osales 1209 siiratud neeruga patsienti, võrreldi Nulojixi tsüklosporiin A-ga (samuti elundi äratõukereaktsiooni ennetav ravim).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nulojix.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Nulojix, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Nulojixi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Although the studies showed more acute rejections after one year of treatment with Nulojix compared with cyclosporine A, this did not lead to reduced patient and organ survival after three years.
Estonian: Kuigi võrreldes tsüklosporiin A-ga esines Nulojix-ravi saanutel ühe aasta jooksul pärast siirdamist rohkem äratõukereaktsioone, ei esinenud kolme aasta järel väiksemat patsientide ja organite elulemust.
English: The active substance in Nulojix, belatacept, is an immunosuppressive medicine.
Estonian: Nulojixi toimeaine belatatsept on immunosupressant.
English: Overall, the benefits of Nulojix compared well with the comparator medicine.
Estonian: Kokkuvõtteks oli Nulojixi kasulikkus võrreldav võrdlusravimiga.
English: Intensive Nulojix treatment with a longer initial phase of six months produced similar results to treatment with a three-month initial phase.
Estonian: Intensiivne ravi Nulojixiga ja pikem, 6-kuuline algfaas andis sarnased tulemused kui 3-kuuline algfaas.
English: What is the risk associated with Nulojix?
Estonian: Mis riskid Nulojixiga kaasnevad?
English: All patients were also treated with corticosteroids, mycophenolic acid, and basiliximab (an interleukin-2 receptor antagonist) during the first week after transplantation.
Estonian: Kõik patsiendid said esimesel siirdamisjärgsel nädalal lisaks ka kortikosteroide, mükofenoolhapet ja basiliksimaabi (interleukiin-2 retseptori antagonist).
English: It suppresses the activity of ‘T cells', immune system cells that can become involved in organ rejection.
Estonian: See pärsib T-rakkude (immuunsüsteemi rakud, mis on seotud elundi äratõukereaktsiooniga) aktiivsust.
English: Nulojix is a powder that is made up into a solution for infusion (drip into a vein).
Estonian: Nulojix on infusioonilahuse (veeni tilgutatava lahuse) pulber.
English: What is Nulojix?
Estonian: Mis on Nulojix?
English: Nulojix should only be prescribed and supervised by a doctor who has experience in the management of kidney transplant patients.
Estonian: Nulojixi tohib määrata ja selle kasutamist jälgida üksnes siiratud neeruga patsientide ravis kogenud arst.
English: Some patients were given intensive Nulojix treatment which involved a longer initial phase of six months.
Estonian: Osale patsientidest manustati Nulojixi intensiivselt, mille korral oli algfaas pikem - kuus kuud.
English: Around 54% of patients receiving Nulojix and 78% of those receiving cyclosporine A had impaired kidney function.
Estonian: Ligikaudu 54%-l Nulojixi saanud patsientidest ja 78%-l tsüklosporiin A-d saanud patsientidest tekkis neerufunktsiooni häire.
English: In the first study, 97% of patients receiving Nulojix treatment survived with their kidneys intact (218 out of 226) compared with 93% of patients receiving cyclosporine A (206 out 221).
Estonian: Esimeses uuringus jäi kahjustamata neeruga elama 97% Nulojixi saanud patsientidest (218 patsienti 226-st), tsüklosporiin A-d saanud patsientide grupis oli see näitaja 93% (206 patsienti 221-st).
English: Why has Nulojix been approved?
Estonian: Miks Nulojix heaks kiideti?
English: It is used with corticosteroids and a mycophenolic acid (other medicines used to prevent organ rejection).
Estonian: Ravimit kasutatakse koos kortikosteroidide ja mükofenoolhappega (samuti äratõukereaktsiooni ennetavad ravimid).
English: In the second study, 89% (155 out of 175) of patients on Nulojix and 85% (157 out 184) of those on cyclosporine A survived with their kidneys intact.
Estonian: Teises uuringus jäi kahjustamata neeruga elama 89% Nulojixiga ravitud patsientidest (155 patsienti 175-st) ja 85% tsüklosporiin A-d saanud patsientidest (157 patsienti 184-st).
English: For the full list of all side effects reported with Nulojix, see the package leaflet.
Estonian: Nulojixi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: An interleukin-2 receptor antagonist medicine should also be used with Nulojix during the first week after the kidney transplant.
Estonian: Esimesel nädalal pärast neeru siirdamist tuleb koos Nulojixiga kasutada ka interleukiin-2 retseptori antagonisti.
English: It contains the active substance belatacept.
Estonian: Ravim sisaldab toimeainena belatatsepti.
English: What benefit has Nulojix shown during the studies?
Estonian: Milles seisneb uuringute põhjal Nulojixi kasulikkus?
English: Nulojix is used in adults to prevent the body from rejecting a transplanted kidney.
Estonian: Nulojixi kasutatakse täiskasvanud patsientidel siiratud neeru äratõukereaktsiooni ennetamiseks.
English: How is Nulojix used?
Estonian: Kuidas Nulojixi kasutatakse?
English: The proportion of patients who had an episode of organ rejection within one year was 17% for Nulojix and 7% for cyclosporine A.
Estonian: Ühe aasta jooksul esines elundi äratõukereaktsioone 17%-l Nulojixi saanud patsientidest ja 7%-l tsüklosporiin A-d saanud patsientidest.
English: How has Nulojix been studied?
Estonian: Kuidas Nulojixi uuriti?
English: This stops them activating the T cells, helping to prevent organ rejection.
Estonian: See takistab molekulidel T-rakkude aktiveerimist, pärssides äratõukereaktsiooni.
English: How does Nulojix work?
Estonian: Kuidas Nulojix toimib?
English: What is Nulojix used for?
Estonian: Milleks Nulojixi kasutatakse?
English: The proportion of patients with impaired kidney function was 77% in patients on Nulojix and 85% in patients on cyclosporine A. Around 18% of patients on Nulojix had an episode of organ rejection within one year compared with 14% of patients on cyclosporine A.
Estonian: Neerufunktsiooni häire esines 77%-l Nulojixiga ravitud patsientidest ja 85%-l tsüklosporiin A-ga ravitud patsientidest.
English: Further information on Zessly can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Zessly kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Zessly?
Estonian: Mis meetmed võetakse, et tagada Zessly ohutu ja efektiivne kasutamine?
English: Zessly (infliximab)
Estonian: Zessly (infliksimab)
English: Other information about Zessly
Estonian: Muu teave Zessly kohta
English: After the initial doses, it is usually given once every 8 weeks.
Estonian: Pärast algannuseid manustatakse seda enamasti iga 8 nädala järel.
English: This means that it is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Zessly on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
English: What is Zessly and what is it used for?
Estonian: Mis on Zessly ja milleks seda kasutatakse?
English: Zessly is used mainly in adults, usually when other medicines or treatments have failed or cannot be used.
Estonian: Zesslyt kasutatakse peamiselt täiskasvanutel ja enamasti juhul, kui muud ravimid või raviskeemid ei ole toiminud või neid ei saa kasutada.
English: Therefore, the Agency's view was that, as for Remicade, the benefit of Zessly outweighs the identified risk and it can be authorised.
Estonian: Seetõttu on amet arvamusel, et nagu ka Remicade korral, ületab Zessly kasulikkus sellega kaasnevad riskid ja seda võib kasutada.
English: To reduce the risk of infusion reactions, patients may be given other medicines before or during treatment with Zessly or the infusion may be slowed down.
Estonian: Infusioonireaktsioonide riski vähendamiseks võidakse patsientidele anda Zesslyga toimuva ravi eel või ajal muid ravimeid, samuti võidakse infusiooni aeglustada.
English: For Crohn's disease and ulcerative colitis, it is also used in children from 6 years of age.
Estonian: Crohni tõve ja haavandilise koliidi korral kasutatakse seda ka lastel alates 6. eluaastast.
English: Zessly must also not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body).
Estonian: Zesslyt ei tohi kasutada ka patsiendid, kellel on tuberkuloos, muud rasked infektsioonid või mõõdukas või raske südamepuudulikkus (süda ei suuda pumbata organismi piisaval hulgal verd).
English: Side effects reported with Zessly are carefully evaluated and any necessary action taken to protect patients.
Estonian: Zessly kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: What are the risks associated with Zessly?
Estonian: Mis riskid Zesslyga kaasnevad?
English: A similar proportion of patients achieved a 20% reduction with the two medicines (around 61.1% with Zessly and 63.5% with Remicade).
Estonian: Kahe ravimi uuringurühmades oli ACR-skoori 20% vähenemise saavutanud patsientide osakaal sarnane - Zessly rühmas ligikaudu 61,1% ja Remicade rühmas 63,5%.
English: As for all medicines, data on the use of Zessly are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Zessly kasutamise kohta pidevat järelevalvet.
English: For some conditions, Zessly is also used in combination with another medicine, methotrexate.
Estonian: Teatud haigusseisundite korral kasutatakse Zesslyt ka koos teise ravimi, metotreksaadiga.
English: In particular, information will be provided for doctors who intend to prescribe the medicine to children with Crohn's disease or ulcerative colitis, to explain that these patients may be at an increased risk of developing infections and to remind of the importance of keeping vaccinations up to date.
Estonian: Eelkõige antakse teavet arstidele, kes kavatsevad määrata ravimit Crohni tõve või haavandilise koliidiga lastele, selgitades, et neil patsientidel võib olla suurem infektsioonide tekkerisk, ning rõhutades vaktsineerimiskava järgimise tähtsust.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Zessly has been shown overall to have a comparable quality, safety and effectiveness to Remicade.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Zessly võrreldav kvaliteedi-, ohutus- ja efektiivsusprofiil Remicade profiiliga.
English: The most common side effects with Zessly (seen in more than 1 patient in 10) are viral infections (such as flu and cold sores), headache, upper respiratory tract infection (nose and throat infection), sinusitis (inflammation of the sinuses), nausea (feeling sick), abdominal pain (stomach ache), infusionrelated reactions and pain.
Estonian: Zessly kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on viirusinfektsioonid (nt gripp ja vöötohatis), peavalu, ülemiste hingamisteede infektsioonid (nina-neeluinfektsioonid), sinusiit (põskkoopapõletik), iiveldus, kõhuvalu, infusiooniga seotud reaktsioonid ja valu.
English: For more information about using Zessly, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Zessly kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Zessly is an anti-inflammatory medicine for treating the following diseases:
Estonian: Zessly on põletikuvastane ravim, mis on näidustatud järgmiste haiguste raviks:
English: Because Zessly is a biosimilar medicine, the studies on effectiveness and safety carried out with Remicade do not all need to be repeated for Zessly.
Estonian: Et Zessly on bioloogiliselt sarnane ravim, ei pea Remicadega tehtud efektiivsus- ja ohutusuuringuid Zesslyga kordama.
English: By attaching to TNF-α, infliximab blocks its activity and thereby reduces inflammation and other symptoms of the diseases.
Estonian: Kasvaja α-nekroositeguriga seondudes blokeerib infliksimab virgatsaine toime ning vähendab seeläbi põletikku ja muid haiguste sümptomeid.
English: After each infusion, the patient should be monitored for 1 to 2 hours in case they have an allergic reaction, such as swelling of the mouth, face and throat, skin rash, and difficulty breathing.
Estonian: Pärast iga infusiooni tuleb patsienti 1-2 tunni jooksul jälgida võimaliku allergilise reaktsiooni suhtes, näiteks suu-, näo- ja kõriturse, nahalööve ja hingamisraskused.
English: The study looked at the proportion of patients who achieved at least a 20% reduction in ACR scores (a measure of painful, swollen joints and other symptoms) after 14 weeks of treatment.
Estonian: Uuringus hinnati nende patsientide osakaalu, kelle ACR-skoorid (valusate, turses liigeste ja muude sümptomite mõõdikud) vähenesid pärast 14-nädalast ravi vähemalt 20%.
English: In addition, Zessly was as effective as Remicade in a study of 650 rheumatoid arthritis patients whose previous treatment with methotrexate alone had not worked well enough.
Estonian: Peale selle oli Zessly uuringus, milles osales 650 reumatoidartriidiga patsienti, kelle eelnev ravi ainult metotreksaadiga ei olnud piisavalt hästi toiminud, sama efektiivne kui Remicade.